[4] In 2009, as the swine flu outbreak was spreading across the globe and various health organizations and government agencies were piling up stocks of Oseltamivir as precautionary measures, Hetero supplied generic Oseltamivir under its brand name Fluvir.

[7] Hetero received its second order from Indian government to supply another 10 million doses of Oseltamivir later in 2009.

[8] The company has launched the generic version of experimental COVID-19 drug Remdesivir under brand name Covifor after acquiring license from Gilead Sciences and obtaining approval from CDSCO, the Indian drug control authority.

[9] On 29 July 2020, the company launched its version of the anti viral drug Favipiravir under the brand name Favivir, after getting approval from Drugs Controller General of India (DCGI), used in the treatment of mild to moderate COVID-19 patients.

[10] On 27 November 2020, Hetero Labs signed an agreement with the Russian Direct Investment Fund (RDIF) to manufacture 100 million doses of the Sputnik V vaccine.